Deutsche Bank AG Purchases Shares of 1,349,544 Becton, Dickinson and Company $BDX

Deutsche Bank AG purchased a new stake in Becton, Dickinson and Company (NYSE:BDX) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 1,349,544 shares of the medical instruments supplier’s stock, valued at approximately $204,226,000. Deutsche Bank AG owned 0.49% of Becton, Dickinson and Company at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Imprint Wealth LLC acquired a new position in shares of Becton, Dickinson and Company in the 3rd quarter valued at $25,000. SHP Wealth Management acquired a new stake in shares of Becton, Dickinson and Company during the 4th quarter valued at about $26,000. Prosperity Bancshares Inc purchased a new position in shares of Becton, Dickinson and Company in the 4th quarter valued at about $29,000. WPG Advisers LLC raised its holdings in Becton, Dickinson and Company by 64.2% in the 4th quarter. WPG Advisers LLC now owns 156 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 61 shares during the period. Finally, Kohmann Bosshard Financial Services LLC acquired a new stake in Becton, Dickinson and Company in the fourth quarter valued at approximately $32,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Insider Activity

In other news, EVP Roland Goette sold 2,438 shares of the company’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total value of $440,887.92. Following the completion of the sale, the executive vice president directly owned 14,856 shares in the company, valued at $2,686,559.04. This represents a 14.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Michael David Garrison sold 1,100 shares of Becton, Dickinson and Company stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total value of $160,226.00. Following the transaction, the executive vice president owned 13,172 shares in the company, valued at approximately $1,918,633.52. The trade was a 7.71% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 11,779 shares of company stock worth $1,974,669 over the last ninety days. Corporate insiders own 0.40% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on BDX shares. The Goldman Sachs Group decreased their target price on Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 27th. TD Cowen upped their price objective on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the stock a “hold” rating in a research report on Wednesday, August 5th. Wells Fargo & Company increased their price objective on shares of Becton, Dickinson and Company from $161.00 to $170.00 and gave the company an “equal weight” rating in a report on Friday, August 7th. Bank of America dropped their target price on shares of Becton, Dickinson and Company from $177.00 to $170.00 in a research report on Friday, June 12th. Finally, Jefferies Financial Group reissued a “buy” rating and set a $210.00 target price on shares of Becton, Dickinson and Company in a research note on Thursday, August 6th. Eight equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Becton, Dickinson and Company presently has an average rating of “Hold” and an average target price of $185.67.

Becton, Dickinson and Company Trading Down 0.5%

Shares of BDX stock opened at $181.17 on Wednesday. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $187.35. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87. The stock’s fifty day moving average is $159.06 and its two-hundred day moving average is $161.12. The firm has a market capitalization of $49.92 billion, a P/E ratio of 54.57, a PEG ratio of 12.93 and a beta of 0.19.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.14 by $0.09. The business had revenue of $4.98 billion during the quarter, compared to analyst estimates of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The company’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Research analysts expect that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be issued a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a dividend yield of 2.3%. The ex-dividend date is Wednesday, September 9th. Becton, Dickinson and Company’s payout ratio is currently 126.51%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.